Your session is about to expire
← Back to Search
Proteinase Inhibitor
α1 Proteinase Inhibitor in HIV disease for HIV/AIDS
Phase 2 & 3
Waitlist Available
Led By Cynthia Bristow, PhD
Research Sponsored by Institute for Human Genetics and Biochemistry
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 weeks after initiation of treatment
Awards & highlights
All Individual Drugs Already Approved
Summary
Our primary objective is to further characterize the mechanism by which alpha-1PI regulates CD4 counts. HIV-1 infected patients will be initiated on PROLASTIN®-C (Alpha-1 Proteinase Inhibitor \[Human\], Grifols Biotherapeutics Inc.) or placebo. Uninfected volunteers will be untreated and will be monitored for comparison.
Eligible Conditions
- HIV/AIDS
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9 weeks after initiation of treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 weeks after initiation of treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
CD4 Counts
CD4/CD8 Ratio
CD8
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: α1 Proteinase Inhibitor in HIV diseaseExperimental Treatment1 Intervention
α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
Group II: Uninfected controlsActive Control1 Intervention
Blood collection only for 8 weeks
Group III: Placebo in HIV diseasePlacebo Group1 Intervention
Placebos weekly for 8 weeks
Find a Location
Who is running the clinical trial?
Institute for Human Genetics and BiochemistryLead Sponsor
1 Previous Clinical Trials
4 Total Patients Enrolled
AIDS Community Research Initiative of AmericaOTHER
Grifols Biologicals, LLCIndustry Sponsor
32 Previous Clinical Trials
9,444 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger